



Contacts: Tularik Inc.
Traci McCarty (investors/media)
650-825-7182

Tularik Announces Underwriters' Exercise of Option to Purchase Additional Shares

South San Francisco, Calif., November 17, 2003 – Tularik Inc. (Nasdaq: TLRK) today announced that the underwriters have purchased an additional 900,000 shares of common stock pursuant to an option granted to the underwriters in connection with the Company's common stock offering, which priced on November 10, 2003. Including the sale of these additional shares the offering totaled 6,900,000 shares of common stock, resulting in net proceeds to the Company of approximately \$77.8 million.

Goldman, Sachs & Co. is the book-running and lead manager for this offering. SG Cowen Securities Corporation, UBS Securities LLC and SunTrust Robinson Humphrey, Inc. are the co-managers.

All of the shares were offered by Tularik under its currently effective shelf registration statement. This communication shall not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.

Copies of the final prospectus supplement and accompanying prospectus may be obtained from the Prospectus Departments of Goldman, Sachs & Co. (85 Broad Street, New York, New York 10004, phone 212-902-1171, fax 212-902-9316).

About Tularik

Tularik is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, immunology and metabolic disease. The Company currently has four drug candidates in clinical trials. In the cancer area, Tularik is currently conducting a pivotal study of T67 for the treatment of hepatocellular carcinoma (HCC) and Phase 2 trials with T607 for the treatment of HCC, ovarian cancer, gastric cancer and esophageal cancer. T487, for the treatment of inflammatory diseases, and T131, for the treatment of type 2 diabetes, are moving into Phase 2 trials.